188804-07-1
Chemical Structure
SC-68448
Synonym(s): S 448
- CAS No.: 188804-07-1
- Formula:C19H19Cl2N5O4
- Molecular Weight:452.29
IUPAC Name: 3-(3,5-dichlorophenyl)-3-(2-(3-guanidinobenzamido)acetamido)propanoic acid
InChIKey: XWMBYGCYHWLPMQ-UHFFFAOYSA-N
SMILES: O=C(O)CC(NC(CNC(C1=CC=CC(NC(N)=N)=C1)=O)=O)C2=CC(Cl)=CC(Cl)=C2
Biological Activity: SC-68448 (S 448) is a selective αvβ3 antagonist (IC50 = 1 nM). SC-68448 inhibits αvβ3-mediated endothelial cell proliferation. SC-68448 reduces the total level of αvβ6 in NHBE cells. SC-68448 inhibits angiogenesis in a rat corneal neoplasia model. SC-68448 inhibits tumor growth and completely prevents the development of hypercalcemia in a rat Ledich cell tumor model. SC-68448 can be used in research on cardiovascular and cerebrovascular diseases such as hypercalcemia and cancers such as testicular interstitial cell tumors[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
SC-68448 | SC-68448 (S 448) is a selective αvβ3 antagonist (IC50 = 1 nM). SC-68448 inhibits αvβ3-mediated endothelial cell proliferation. SC-68448 reduces the total level of αvβ6 in NHBE cells. SC-68448 inhibits angiogenesis in a rat corneal neoplasia model. SC-68448 inhibits tumor growth and completely prevents the development of hypercalcemia in a rat Ledich cell tumor model. SC-68448 can be used in research on cardiovascular and cerebrovascular diseases such as hypercalcemia and cancers such as testicular interstitial cell tumors. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Carron CP,et al. A peptidomimetic antagonist of the integrin alpha(v)beta3 inhibits Leydig cell tumor growth and the development of hypercalcemia of malignancy. Cancer Res. 1998 May 1;58(9):1930-5. [Content Brief]
- [2]. Roper JA, et al. Downregulation of the αvβ6 Integrin via RGD Engagement Is Affinity and Time Dependent. J Pharmacol Exp Ther. 2021 Feb;376(2):273-280. [Content Brief]
